ClinicalTrials.gg
Not yet recruitingNCT07945067Updated Nov 18, 2026

Stigma Reduction Intervention for MSM and Healthcare Providers

An interventional study of DONGHANH INTERVENTION in HIV and Stigma, sponsored by University of Pittsburgh. Not yet recruiting at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study describes only the Aim 2 clinical trial component of the NIH-funded project "Adapting an Intervention to Reduce Stigma among MSM and Healthcare Providers in Vietnam". The purpose of this pilot randomized waitlist-controlled trial (N=180) is to evaluate the preliminary efficacy of DONGHANH, a stigma-reduction intervention for men who have sex with men and healthcare providers in Vietnam. The study will provide preliminary data on the intervention's potential impact to inform the design of a larger future trial evaluating its effects on HIV prevention and care outcomes in Vietnam and in other countries with collectivist cultures.

Read the detailed description

This is a pilot randomized waitlist-controlled trial of DONGHANH, a stigma-reduction intervention for men who have sex with men (MSM) and healthcare providers (HCP) in Vietnam. Participants are randomized 1:1 to receive DONGHANH immediately or to a waitlist control. Waitlist participants receive the same DONGHANH workshops after the 3-month assessment. Assessments occur at baseline and 3 months for all participants. Participants in the immediate intervention arm complete an additional assessment at 6 months. Efficacy outcomes are analyzed using generalized linear mixed models or generalized estimating equations, with the intervention-by-time interaction as the primary test of effect.

02

Conditions studied

  • HIV
  • Stigma

Browse trials for

Keywords

  • Behavioral Intervention
  • intersectional stigma
  • MSM
  • Healthcare providers
  • implementation science
  • e-health
03

In context

Social Stigma

267 studies on the registry are indexed under Social Stigma; 66 are open to participants now.

This study's planned enrollment of 180 is above the median of 142 across 218 interventional studies indexed under Social Stigma.

Browse Social Stigma studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

MSM:

  • Age 18 years or older
  • Cisgender male
  • -positive, HIV-negative, or unknown HIV status
  • Self-reported history of condomless sex
  • Able to provide written

Healthcare providers:

  • Age 18 years or older
  • Works in an HIV outpatient clinic or community-based organization clinic in Hanoi
  • Able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Unable to read and understand Vietnamese
  • Currently enrolled in another intervention study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    DONGHANH Intervention

    DONGHANH is a stigma-reduction intervention for men who have sex with men (MSM) and healthcare provider (HCP) in Vietnam. The intervention is delivered through five workshops attended jointly by MSM and HCP participants. Each workshop lasts approximately 1.5 days and consists of 10 modules. The modules use presentations, group discussions, and interactive exercises to build understanding of HIV-related and sexuality-related stigma; facilitate the sharing of personal experiences of stigma among MSM and HCP participants; explore the health effects of stigma; and develop strengths and strategies for coping with and reducing stigma.

    Behavioral: DONGHANH INTERVENTION

  • Experimental
    Waitlist control group

    Participants in this arm receive no intervention for the first 3 months after randomization. During this period, study staff contact them every 2 weeks to maintain retention. These contacts do not include any intervention content. After the 3-month assessment, participants receive the same DONGHANH workshops Assessments occur at baseline, 3 months and 6 months

    Behavioral: DONGHANH INTERVENTION

Interventions

  • BehavioralDONGHANH INTERVENTION

    DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies.

06

What researchers measure

Primary outcomes

  1. Feasibility of the intervention

    Feasibility of the intervention will be assessed with the feasibility of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater perceived feasibility. Results will be reported separately for among MSM and healthcare providers.

    Time frame: 3 months

  2. Acceptability of of the intervention

    Acceptability of the intervention will be assessed with the acceptability of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater acceptability. Results will be reported separately for MSM and healthcare providers.

    Time frame: 3 months

  3. Appropriateness of the intervention

    Appropriateness of the intervention will be assessed using the intervention appropriateness measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The overall score is calculated as the mean of the four items, ranging from 1 to 5. Higher scores indicate greater perceived appropriateness. Results will be reported separately for MSM and healthcare providers.

    Time frame: 3 months

Secondary outcomes

  1. Changes in stigma

    Change in stigma will be measured using the homosexuality-related stigma scale (Vietnamese version), a self-report measure of stigma among MSM. The scale has three subscales: enacted stigma (7 items, rated 1 \[never\] to 4 \[many times\]), perceived stigma (11 items), and internalized stigma (8 items). Perceived and internalized stigma items are rated 1 (strongly disagree) to 4 (strongly agree). Each subscale score is the mean of its items and ranges from 1 to 4. Higher scores indicate greater stigma. Change is calculated as the 3-month and 6- month score minus the baseline score.

    Time frame: Baseline, 3 months, and 6 months

  2. Change in observed HIV-related stigma in healthcare settings

    Change in observed HIV-related stigma will be measured using 3 items assessing HIV-related stigma among health facility staff. Items ask how often participants observed stigmatizing behaviors in their health facility in the past 12 months (for example, health workers unwilling to care for a patient living with HIV). Each item is rated on a 4-point frequency scale: 1 (never), 2 (once or twice), 3 (several times), and 4 (most of the time). The score is the sum of the 3 items and ranges from 3 to 12. Higher scores indicate more observed stigma.

    Time frame: Baseline, 3 months, and 6 months

07

Study locations

1 site
  • Institute of Social and Medical Studies
    Hanoi, Vietnam
08

References and documents

Publications

  • Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3. PubMed 28851459 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in publications will be deposited in an NIH-supported repository for HIV-related behavioral research. Access will be controlled and subject to a data use agreement prohibiting re-identification and unauthorized disclosure. Given the sensitive nature of HIV-related information and sexual orientation, and the risk of re-identification in small samples, data will be reviewed and de-identified before sharing. Data will be made available in accordance with repository policies and applicable consent, ethical, and institutional requirements, for as long as the repository maintains the data and makes them available.

Supporting information: Statistical analysis plan

Time frame: Data underlying published results will be available upon publication. Any other Aim 2 data will be shared by the end of the award period at the latest. Data will remain available in the repository for a minimum of 7 years.

Access criteria: Data will be available free of charge through the Mendeley Data repository. Users must register with the repository and agree to its terms, which restrict use to scientific research and aggregate statistical reporting. Data will be findable through a digital object identifier assigned by the repository. Access will follow the informed consent and institutional requirements, and any data designated as restricted use will be available under the repository's restricted-access terms.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Jul 2027, 3 months later.

Of 162 non-industry interventional studies with no phase under Social Stigma, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 3 months is below that.

Counting every sponsor, half of 164 studies reached it within 15 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 18, 2026
StartEst.
Apr 1, 2027
Primary completionEst.
Jul 15, 2027
CompletionEst.
Mar 1, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945067
Responsible party
Toan Ha (Assistant professor, University of Pittsburgh) — Principal investigator
First posted
Nov 18, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Jul 15, 2027 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Toan Ha, MD, DrPH
Contact
toh33@pitt.edu
412-383-4576
Toan Ha, MD, DrPH
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion